Nifty, Sensex on continued uptrend– Tuesday closing report
Moneylife Digital Team
0
We had mentioned in Monday’s closing report that Nifty, Sensex were trending up. On Tuesday, the indices opened higher but ended flat. On the NSE, there were 728 advances, 1,245 declines and 57 unchanged
Bajaj Auto reported domestic sales of 60,830 units in May 2021 against 40,074 units in May 2020. Total two-wheeler sales were at 2.40 lakh units against 1.13 lakh units in the year-ago period. Exports were 2.11 lakh units against 87,054 units in May 2020.
TVS Motor Company closed May 2021 selling 166,889 units up from 58,906 units sold in May 2020.
Glenmark Pharmaceuticals Limited announced the launch of Rufinamide tablets, 200 mg and 400 mg, a therapeutic equivalent of Banzel tablets, 200 mg and 400 mg of Eisai, Inc.
Glenmark Pharmaceuticals on Tuesday announced the launch of Rufinamide Tablets USP, 200 mg and 400 mg.
The tablets are a therapeutic equivalent of Banzel Tablets, 200 mg and 400 mg of Eisai Inc. Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA for Rufinamide Tablets USP, 200 mg and 400 mg, with a paragraph IV certification and received final approval on 16 May 2016.
According to IQVIA sales data for the 12-month period ending April 2021, the Banzel Tablets achieved annual sales of approximately $285.3 million.
Commenting on the launch, Sanjeev Krishan, president of Glenmark North America said, We are very pleased to be one of the first generic companies in the US to offer lower cost alternative to Banzel Tablets, 200 mg and 400 mg. The launch is our commitment to provide quality and affordable healthcare to our markets for patients.
URL copied Image Source : PTI/ FILE
Glenmark Pharmaceuticals Ltd has launched Rufinamide tablets USP in the strengths of 200 mg and 400 mg
Glenmark Pharma on Tuesday announced the launch of anti-epileptic drug Rufinamide tablets in the US market. Glenmark Pharmaceuticals Ltd has launched Rufinamide tablets USP in the strengths of 200 mg and 400 mg, the company said in a regulatory filing. The newly launched drug is a therapeutic equivalent of Banzel tablets, 200 mg and 400 mg of Eisai, Inc.
Banzel tablets are used in combination with other medications to treat children with Lennox-Gastaut syndrome, a severe form of childhood epilepsy that also causes developmental and behavior problems. Sanjeev Krishan, President, Glenmark North America said the company is one of the first generic companies in the US to offer lower-cost alternatives to Banzel tablets, 200 mg and 400 mg.
In a statement issued Glenmark said it was one of the first Abbreviated New Drug Application (ANDA) applicants to submit a substantially complete ANDA for Rufinamide tablets.Comm